Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

被引：1
|
作者：
Palazzo, A. [1 ]
Toss, A. [2 ]
Graffeo, R. [3 ]
Fontana, A. [4 ]
Lambertini, M. [5 ]
Pantaleo, F. [4 ]
Perachino, M. [6 ]
Nerone, M. [7 ]
Bianco, N. [8 ]
Vici, P. [9 ]
de Marchis, L. [10 ]
Staropoli, N. [11 ]
Rinaldi, L. [12 ]
Lai, A. [13 ]
Spinelli, G. P. [14 ]
Di Monte, E. [15 ]
Giotta, F. [12 ]
Gennari, A. [16 ]
Cortesi, L. [17 ]
Bria, E. [18 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Comprehens Canc Ctr, Rome, Italy
[2] Azienda Osped Univ Policlin Modena, Dept Oncol & Haematol, Modena, Italy
[3] EOC Osped Reg Lugano Sede Italiano, IOSI, Lugano, Switzerland
[4] AOU Pisana Stabilimento Santa Chiara, Med Oncol, Pisa, Italy
[5] IRCCS AOU San Martino, IST Ist Nazl Ric Cancro, Clin Oncol Med, Genoa, Italy
[6] IRCCS Osped Policlin San Martino, Clin Oncol Dept, Genoa, Italy
[7] EOC Osped Reg Bellinzona & Valli, Ist Oncol Svizzera Italiana IOSI, Reparto Oncol, Bellinzona, Switzerland
[8] IEO Ist Europeo Oncol, Med Senol Dept, Milan, MB, Italy
[9] IRCCS Regina Elena Natl Canc Inst, Phase 4 Clin Study Unit, Rome, Italy
[10] Univ Roma la Sapienza, Fac Med, Radiol Oncol Pathol, Latina, Italy
[11] UMG Univ Magna Graecia Catanzaro, Med Clin & Sperimentale, Catanzaro, Italy
[12] IRCCS, Ist Tumori Bari Giovanni Paolo II, Oncol Inst, Bari, Italy
[13] Mater Olbia Hosp, Dept Oncol, Olbia, Italy
[14] Oncol Univ ASL Aprilia, Dist ASL Latina 1, Aprilia, Italy
[15] Fdn Policlin Univ Agostino Gemelli, IRCCS, Ctr Comprehens Canc, Med Oncol Dept,Unit Med Oncol, Rome, Italy
[16] AOU Maggiore Carita Novara, Dept Translat Med, Novara, Italy
[17] Azienda Osped Univ Policlin Modena, SC Oncol Med, SS Genet Oncol, Modena, Italy
[18] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Translat Med & Surg, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [41] Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
    Litton, Jennifer K.
    Laird, A. Douglas
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Goodwin, Annabel
    Blum, Joanne L.
    Eiermann, Wolfgang
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Albacker, Lee A.
    Frampton, Garrett M.
    Mina, Lida A.
    CANCER RESEARCH, 2020, 80 (16)
  • [42] Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery
    Houvenaeghel, Gilles
    Classe, Jean-Marc
    Chauvet, Marie-Pierre
    Colombo, Pierre-Emmanuel
    Jouve, Eva
    Reyal, Fabien
    Darai, Emile
    Rouzier, Roman
    Faure-Virelizier, Christelle
    Gimbergues, Pierre
    Coutant, Charles
    Mazouni, Chafika
    Azuar, Anne-Sophie
    Martino, Marc
    Bouteille, Catherine
    Cohen, Monique
    de Nonneville, Alexandre
    CANCERS, 2024, 16 (19)
  • [43] A phase Ib trial of fulvestrant+CDK4/6 inhibitor (CDK4/6i) palbociclib plus pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/HER2-negative metastatic breast cancer (MBC)
    Mayer, Ingrid A.
    Haley, Barbara B.
    Abramson, Vandana G.
    Brufsky, Adam
    Rexer, Brent
    Stringer-Reasor, Erica
    Jhaveri, Komal L.
    Sanders, Melinda
    Ericsson-Gonzalez, Paula I.
    Ye, Fei
    Arteaga, Carlos L.
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
    Lin, Mingxi
    Chen, Yang
    Jin, Yizi
    Hu, Xichun
    Zhang, Jian
    JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
  • [45] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer Reply
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Toi, Masakazu
    Martin, Miguel
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1507 - +
  • [46] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Pla, Helena
    Felip, Eudald
    Obadia, Veronica
    Pernas, Sonia
    Vinas, Gemma
    Margeli, Mireia
    Fort-Culillas, Roser
    Del Barco, Sonia
    Sabate, Nuria
    Fort, Eduard
    Lezcano, Clara
    Cirauqui, Beatriz
    Quiroga, Vanesa
    Stradella, Agostina
    Gil, Miguel Gil
    Esteve, Anna
    Recalde, Sabela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
  • [47] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
  • [48] A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Trippa, Lorenzo
    Rees, Rebecca
    Andrews, Chelsea
    Ferreira, Arlindo R.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2-metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
    Weerasena, I.
    Spalding, L.
    Martin, H.
    Redfern, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1263 - S1263
  • [50] Is the percentage of hormone receptor positivity in HR+HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?
    Keskinkilic, Merve
    Semiz, Huseyin Salih
    Yavuzsen, Tugba
    Oztop, Ilhan
    FRONTIERS IN ONCOLOGY, 2024, 14
12345